HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tanja Fehm Selected Research

Anthracyclines

1/2022The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
1/2018Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
1/2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
8/2017High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy.
11/2016Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).
6/2011Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
9/2010Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
5/2008Changes in tumour biological markers during primary systemic chemotherapy (PST).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tanja Fehm Research Topics

Disease

164Breast Neoplasms (Breast Cancer)
05/2024 - 09/2002
123Neoplasms (Cancer)
01/2024 - 07/2002
38Circulating Neoplastic Cells
01/2024 - 12/2004
19Neoplasm Metastasis (Metastasis)
02/2022 - 09/2002
14Ovarian Neoplasms (Ovarian Cancer)
02/2022 - 06/2004
7Disease Progression
01/2023 - 01/2007
7Carcinogenesis
01/2020 - 02/2009
6Residual Neoplasm
02/2022 - 01/2008
5Uterine Cervical Neoplasms (Cancer of the Cervix)
10/2023 - 01/2012
4Pain (Aches)
07/2022 - 09/2017
4Noninfiltrating Intraductal Carcinoma (DCIS)
12/2021 - 01/2015
4Carcinoma (Carcinomatosis)
07/2013 - 09/2010
3Pathologic Complete Response
01/2023 - 01/2018
3Inflammation (Inflammations)
02/2021 - 01/2008
3Triple Negative Breast Neoplasms
12/2020 - 01/2018
3Hemorrhage
01/2019 - 01/2012
3Prostatic Neoplasms (Prostate Cancer)
11/2018 - 01/2013
3Lymphatic Metastasis
09/2010 - 08/2005
2Endometriosis
12/2023 - 02/2021
2Fibrosis (Cirrhosis)
07/2022 - 04/2020
2Arthralgia (Joint Pain)
08/2021 - 10/2019
2Vulvar Neoplasms (Vulvar Cancer)
12/2020 - 01/2016
2Hypertension (High Blood Pressure)
01/2020 - 01/2012

Drug/Important Bio-Agent (IBA)

39Hormones (Hormone)IBA
12/2023 - 08/2005
23Progesterone Receptors (Progesterone Receptor)IBA
11/2021 - 09/2005
21Biomarkers (Surrogate Marker)IBA
02/2022 - 05/2004
14Proteins (Proteins, Gene)FDA Link
04/2020 - 06/2004
12Epithelial Cell Adhesion MoleculeIBA
01/2023 - 11/2007
11Estrogen ReceptorsIBA
12/2020 - 09/2002
10Trastuzumab (Herceptin)FDA Link
03/2023 - 06/2004
10Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 05/2010
9Estrogens (Estrogen)FDA Link
12/2023 - 09/2005
9DNA (Deoxyribonucleic Acid)IBA
01/2023 - 11/2007
9Docetaxel (Taxotere)FDA Link
10/2018 - 05/2010
8AnthracyclinesIBA
01/2022 - 05/2008
7RNA (Ribonucleic Acid)IBA
12/2023 - 05/2006
7Progestins (Progestagens)IBA
11/2021 - 04/2011
7Diphosphonates (Bisphosphonates)IBA
08/2021 - 07/2012
6human ERBB2 proteinIBA
01/2023 - 01/2012
6taxaneIBA
01/2022 - 05/2008
6Zoledronic Acid (Zometa)FDA Link
08/2021 - 07/2012
6Epirubicin (Ellence)FDA LinkGeneric
01/2018 - 05/2010
6PlatinumIBA
11/2016 - 11/2007
5pertuzumabIBA
03/2023 - 03/2013
5ErbB Receptors (EGF Receptor)IBA
01/2023 - 01/2007
5Aromatase InhibitorsIBA
12/2020 - 09/2010
5Bevacizumab (Avastin)FDA Link
01/2020 - 01/2012
5Doxorubicin (Adriamycin)FDA LinkGeneric
11/2016 - 01/2003
5Estrogen Receptor alphaIBA
01/2016 - 01/2008
5Keratins (Keratin)IBA
01/2008 - 07/2002
4Letrozole (Femara)FDA LinkGeneric
12/2023 - 01/2017
4AntibodiesIBA
01/2023 - 03/2013
4Paclitaxel (Taxol)FDA LinkGeneric
06/2022 - 11/2007
4Phenobarbital (Luminal)FDA Link
11/2020 - 01/2015
4Protein Isoforms (Isoforms)IBA
01/2020 - 01/2008
4Carboplatin (JM8)FDA LinkGeneric
01/2020 - 11/2007
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 01/2012
4ProgesteroneFDA LinkGeneric
12/2016 - 04/2011
4Monoclonal AntibodiesIBA
07/2014 - 01/2008
4AntigensIBA
04/2014 - 11/2007
4Adenosine Triphosphate (ATP)IBA
08/2012 - 03/2008
3trastuzumab deruxtecanIBA
05/2024 - 01/2023
3Capecitabine (Xeloda)FDA Link
02/2022 - 05/2010
3Norethindrone (Norethisterone)FDA LinkGeneric
11/2021 - 05/2013
3TamoxifenFDA LinkGeneric
12/2020 - 05/2006
3LigandsIBA
01/2020 - 01/2013
3Messenger RNA (mRNA)IBA
01/2020 - 01/2003
3Fluorouracil (Carac)FDA LinkGeneric
01/2018 - 07/2012
3Tumor Biomarkers (Tumor Markers)IBA
09/2015 - 05/2005
3Estradiol (Delestrogen)FDA LinkGeneric
02/2015 - 08/2011
3Indicators and Reagents (Reagents)IBA
02/2012 - 01/2009
2Ado-Trastuzumab EmtansineIBA
05/2024 - 01/2023
2Lapatinib (GW572016)FDA Link
01/2024 - 01/2018
2ribociclibIBA
12/2023 - 01/2022
2DenosumabFDA Link
01/2023 - 07/2014
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
02/2022 - 05/2021
2Vinorelbine (Navelbine)FDA LinkGeneric
11/2021 - 08/2013
2LipidsIBA
01/2021 - 01/2020
2eribulinFDA Link
04/2020 - 02/2016
2CytokinesIBA
01/2020 - 11/2018
2Carbonic Anhydrase IXIBA
01/2019 - 07/2011

Therapy/Procedure

86Therapeutics
01/2024 - 09/2002
50Drug Therapy (Chemotherapy)
01/2023 - 11/2007
24Neoadjuvant Therapy
03/2023 - 01/2006
11Radiotherapy
07/2022 - 09/2010
10Adjuvant Chemotherapy
08/2021 - 06/2011
4Segmental Mastectomy (Lumpectomy)
08/2022 - 07/2018
3Hysterectomy
10/2023 - 07/2011
3Aftercare (After-Treatment)
01/2023 - 10/2018
3Immunotherapy
02/2022 - 11/2020
3Palliative Care (Palliative Therapy)
02/2022 - 08/2011
3Lymph Node Excision (Lymph Node Dissection)
11/2021 - 09/2005
3Chemoradiotherapy
04/2020 - 09/2010
3Mastectomy (Mammectomy)
04/2020 - 12/2004
3Lasers (Laser)
09/2018 - 05/2006
2Combination Drug Therapy (Combination Chemotherapy)
06/2022 - 11/2016
2Brachytherapy
02/2022 - 02/2022
2Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
02/2022 - 02/2022
2Hormone Replacement Therapy (Therapy, Hormone Replacement)
11/2021 - 09/2017
2Duration of Therapy
08/2021 - 10/2011